## Jacek Rysz

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3715958/publications.pdf

Version: 2024-02-01

270 papers 9,859 citations

51
h-index

83 g-index

281 all docs

281 docs citations

times ranked

281

11938 citing authors

#	Article	IF	CITATIONS
1	Position paper Statin intolerance $\hat{a}\in$ an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Archives of Medical Science, 2015, 1, 1-23.	0.4	311
2	Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study. Journal of Psychosomatic Research, 2010, 69, 179-185.	1.2	217
3	The Role of Nutraceuticals in StatinÂIntolerant Patients. Journal of the American College of Cardiology, 2018, 72, 96-118.	1.2	216
4	Effects of Quercetin on Blood Pressure: A Systematic Review and Metaâ€Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 2016, 5, .	1.6	207
5	Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?. Progress in Lipid Research, 2012, 51, 314-324.	5.3	187
6	Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome. International Journal of Molecular Sciences, 2017, 18, 1702.	1.8	183
7	Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Medicine, 2015, 13, 229.	2.3	169
8	The role of Toll-like receptors in renal diseases. Nature Reviews Nephrology, 2010, 6, 224-235.	4.1	168
9	Effects of Coenzyme Q10 on Statin-Induced Myopathy. Mayo Clinic Proceedings, 2015, 90, 24-34.	1.4	168
10	Lipid-modifying effects of nutraceuticals: An evidence-based approach. Nutrition, 2016, 32, 1179-1192.	1.1	157
11	Analysis of vitamin D levels in patients with and without statin-associated myalgia — A systematic review and meta-analysis of 7 studies with 2420 patients. International Journal of Cardiology, 2015, 178, 111-116.	0.8	154
12	Prevalence of statin intolerance: a meta-analysis. European Heart Journal, 2022, 43, 3213-3223.	1.0	151
13	Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials. Pharmacological Research, 2015, 99, 329-336.	3.1	145
14	The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis. Atherosclerosis, 2017, 265, 275-282.	0.4	144
15	Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis, 2016, 253, 194-208.	0.4	142
16	Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. Atherosclerosis, 2015, 241, 433-442.	0.4	139
17	Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors — Results from a systematic review and meta-analysis of randomized controlled trials. International Journal of Cardiology, 2015, 189, 47-55.	0.8	138
18	The impact of statin therapy on plasma levels of von Willebrand factor antigen. Thrombosis and Haemostasis, 2016, 115, 520-532.	1.8	138

#	Article	IF	CITATIONS
19	A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Scientific Reports, 2015, 5, 9902.	1.6	133
20	Association between statin use and plasma D-dimer levels. Thrombosis and Haemostasis, 2015, 114, 546-557.	1.8	127
21	Risk Factors of Atrial Fibrillation Following Coronary Artery Bypass Grafting. Circulation Journal, 2006, 70, 438-441.	0.7	118
22	Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opinion on Drug Safety, 2015, 14, 935-955.	1.0	117
23	The Impact of CKD on Uremic Toxins and Gut Microbiota. Toxins, 2021, 13, 252.	1.5	114
24	Effect of sour tea (Hibiscus sabdariffa L.) on arterial hypertension. Journal of Hypertension, 2015, 33, 1119-1127.	0.3	102
25	The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk. Lipids in Health and Disease, 2017, 16, 207.	1.2	95
26	Obesity indices and inflammatory markers in obese non-diabetic normo- and hypertensive patients: a comparative pilot study. Lipids in Health and Disease, 2014, 13, 29.	1.2	92
27	Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapyâ€"A meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacological Research, 2013, 72, 35-44.	3.1	90
28	The mechanisms of atrial fibrillation in hyperthyroidism. Thyroid Research, 2009, 2, 4.	0.7	85
29	Takotsubo cardiomyopathy â€" The current state of knowledge. International Journal of Cardiology, 2010, 142, 120-125.	0.8	78
30	PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Archives of Medical Science, 2021, 17, 1447-1547.	0.4	78
31	Lipids, blood pressure and kidney update 2014. Pharmacological Research, 2015, 95-96, 111-125.	3.1	77
32	The risk of atherosclerosis in patients with chronic kidney disease. International Urology and Nephrology, 2013, 45, 1605-1612.	0.6	76
33	Blood serum levels of IL-2, IL-6, IL-8, TNF-alpha and IL-1beta in patients on maintenance hemodialysis. Cellular and Molecular Immunology, 2006, 3, 151-4.	4.8	75
34	Metabolic syndrome and renal disease. International Journal of Cardiology, 2013, 164, 141-150.	0.8	74
35	The Effect of Diet on the Survival of Patients with Chronic Kidney Disease. Nutrients, 2017, 9, 495.	1.7	71
36	PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. Archives of Medical Science, 2017, 1, 1-45.	0.4	70

#	Article	IF	CITATIONS
37	The Influence of Inflammation on Anemia in CKD Patients. International Journal of Molecular Sciences, 2020, 21, 725.	1.8	68
38	A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?. International Journal of Cardiology, 2013, 168, 5437-5447.	0.8	66
39	Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy. Journal of Nephrology, 2007, 20, 444-52.	0.9	66
40	State of the art papers Lipids, blood pressure, kidney – what was new in 2011?. Archives of Medical Science, 2011, 6, 1055-1066.	0.4	63
41	Vegetarian Diet in Chronic Kidney Disease—A Friend or Foe. Nutrients, 2017, 9, 374.	1.7	63
42	Statin Therapy and New-onset Diabetes: Molecular Mechanisms and Clinical Relevance. Current Pharmaceutical Design, 2013, 19, 4904-4912.	0.9	62
43	Lipid, blood pressure and kidney update 2013. International Urology and Nephrology, 2014, 46, 947-961.	0.6	60
44	Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. Pharmacological Research, 2016, 103, 236-252.	3.1	60
45	Molecular mechanisms of statin intolerance. Archives of Medical Science, 2016, 3, 645-658.	0.4	58
46	Antioxidant Properties of Carnosine Re-Evaluated with Oxidizing Systems Involving Iron and Copper lons. Basic and Clinical Pharmacology and Toxicology, 2005, 96, 352-360.	1.2	57
47	Predictors of paroxysmal atrial fibrillation in patients undergoing aortic valve replacement. Journal of Thoracic and Cardiovascular Surgery, 2007, 134, 1569-1576.	0.4	57
48	The meaning of hypokalemia in heart failure. International Journal of Cardiology, 2012, 158, 12-17.	0.8	55
49	Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. Scientific Reports, 2016, 6, 19188.	1.6	55
50	The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease. International Journal of Molecular Sciences, 2020, 21, 601.	1.8	54
51	Waist circumference, ghrelin and selected adipose tissue-derived adipokines as predictors of insulin resistance in obese patients: Preliminary results. Medical Science Monitor, 2011, 17, PR13-PR18.	0.5	52
52	PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?. Current Pharmaceutical Design, 2013, 19, 3869-3877.	0.9	52
53	An update on biomarkers of heart failure in hypertensive patients. Journal of Hypertension, 2012, 30, 1681-1689.	0.3	51
54	Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hypertensive patients - pilot study. Archives of Medical Science, 2012, 8, 431-6.	0.4	51

#	Article	IF	Citations
55	Time for new indications for statins?. Medical Science Monitor, 2009, 15, MS1-5.	0.5	51
56	Lone atrial fibrillation: what do we know?. Heart, 2010, 96, 498-503.	1.2	50
57	The Clinical Manifestation of Myocardial Infarction in Elderly Patients. Clinical Cardiology, 2009, 32, E46-51.	0.7	49
58	Postoperative Atrial Fibrillation - What Do We Really Know?. Current Vascular Pharmacology, 2010, 8, 553-572.	0.8	49
59	Lipids, blood pressure and kidney update 2015. Lipids in Health and Disease, 2015, 14, 167.	1.2	49
60	Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. Atherosclerosis, 2015, 242, 87-96.	0.4	47
61	HSP 70 and atherosclerosis – protector or activator?. Expert Opinion on Therapeutic Targets, 2009, 13, 307-317.	1.5	46
62	Malignancy-Associated Dyslipidemia. Open Cardiovascular Medicine Journal, 2011, 5, 35-40.	0.6	46
63	The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe. Current Cardiovascular Risk Reports, 2011, 5, 174-179.	0.8	46
64	Defining the Role of Trimetazidine in the Treatment of Cardiovascular Disorders: Some Insights on Its Role in Heart Failure and Peripheral Artery Disease. Drugs, 2014, 74, 971-980.	4.9	46
65	Temperature and pH dual-responsive coatings of oligoperoxide-graft-poly(N-isopropylacrylamide): Wettability, morphology, and protein adsorption. Journal of Colloid and Interface Science, 2012, 387, 95-105.	5.0	45
66	Effects of supplementation with green tea catechins on plasma C-reactive protein concentrations: A systematic review and meta-analysis of randomized controlled trials. Nutrition, 2015, 31, 1061-1071.	1.1	45
67	Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. Cardiovascular Drugs and Therapy, 2017, 31, 419-431.	1.3	45
68	The significance of preoperative atrial fibrillation in patients undergoing cardiac surgery: preoperative atrial fibrillation-still underestimated opponent. Europace, 2008, 10, 1266-1270.	0.7	44
69	Heart failure biomarkers in patients with dilated cardiomyopathy. International Journal of Cardiology, 2013, 168, 2404-2410.	0.8	43
70	The Role of Polymorphisms Within Paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the Modulation of Cardiovascular Risk: A Pilot Study. Angiology, 2010, 61, 157-165.	0.8	42
71	Predictors of Insulin Resistance in Patients With Obesity. Angiology, 2014, 65, 22-30.	0.8	42
72	Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview. Archives of Medical Science, 2018, 14, 890-909.	0.4	42

#	Article	IF	CITATIONS
73	Serum NGAL, KIM-1, IL-18, L-FABP: new biomarkers in the diagnostics of acute kidney injury (AKI) following invasive cardiology procedures. International Urology and Nephrology, 2020, 52, 2135-2143.	0.6	41
74	Role and significance of statins in the treatment of hypertensive patients. Current Medical Research and Opinion, 2009, 25, 1995-2005.	0.9	40
75	Markers of increased cardiovascular risk in patients with chronic kidney disease. Lipids in Health and Disease, 2014, 13, 135.	1.2	40
76	Pharmacogenomics of Hypertension Treatment. International Journal of Molecular Sciences, 2020, 21, 4709.	1.8	40
77	Nitric oxide release in the peripheral blood during hemodialysis. Kidney International, 1997, 51, 294-300.	2.6	39
78	Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials. Nutrition Reviews, 2017, 75, 361-373.	2.6	39
79	Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opinion on Therapeutic Targets, 2009, 13, 541-550.	1.5	38
80	Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial. Nephrology Dialysis Transplantation, 2017, 32, 1530-1539.	0.4	38
81	Effects of uraemia and haemodialysis on neutrophil apoptosis and expression of apoptosis-related proteins. Nephrology Dialysis Transplantation, 2003, 18, 2582-2588.	0.4	37
82	Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hypertensive patients – pilot study. Archives of Medical Science, 2012, 3, 431-436.	0.4	37
83	The effects of statins on blood pressure in normotensive or hypertensive subjects â€" A meta-analysis of randomized controlled trials. International Journal of Cardiology, 2013, 168, 2816-2824.	0.8	37
84	Circadian changes in the hemostatic system in healthy men and patients with cardiovascular diseases. Medical Science Monitor, 2009, 15, 203-208.	0.5	37
85	Obesity indices and adipokines in non-diabetic obese patients with early stages of chronic kidney disease. Medical Science Monitor, 2013, 19, 1063-1072.	0.5	37
86	Arterial Hypertensionâ€"Oxidative Stress and Inflammation. Antioxidants, 2022, 11, 172.	2.2	37
87	Natriuretic peptides in cardiovascular diseases. Cellular and Molecular Biology Letters, 2008, 13, 155-81.	2.7	36
88	Relation Between Postoperative Mortality and Atrial Fibrillation Before Surgical Revascularization - 3-Year Follow-Up. Thoracic and Cardiovascular Surgeon, 2008, 56, 20-23.	0.4	36
89	The Use of DSM-IV and ICD-10 Criteria and Diagnostic Scales for Delirium Among Cardiac Surgery Patients: Results From the IPDACS Study. Journal of Neuropsychiatry and Clinical Neurosciences, 2010, 22, 426-432.	0.9	36
90	Left atrial size in hypertension and stroke. Journal of Hypertension, 2011, 29, 1988-1993.	0.3	36

#	Article	IF	Citations
91	Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. Current Medical Research and Opinion, 2013, 29, 435-451.	0.9	36
92	The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Medical Science Monitor, 2009, 15, MS12-23.	0.5	36
93	Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease. Journal of Nephrology, 2011, 24, 717-722.	0.9	35
94	Lipoprotein(a) Levels in Patients With Abdominal Aortic Aneurysm. Angiology, 2017, 68, 99-108.	0.8	35
95	The role of polyphenols in cardiovascular disease. Medical Science Monitor, 2010, 16, RA110-9.	0.5	35
96	Telomere attrition, kidney function, and prevalent chronic kidney disease in the United States. Oncotarget, 2017, 8, 80175-80181.	0.8	34
97	Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis. International Urology and Nephrology, 2011, 43, 491-498.	0.6	33
98	New Obesity Indices and Adipokines in Normotensive Patients and Patients With Hypertension. Angiology, 2014, 65, 333-342.	0.8	33
99	The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension. International Journal of Molecular Sciences, 2015, 16, 10715-10733.	1.8	33
100	Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies. International Journal of Cardiology, 2016, 221, 1073-1080.	0.8	33
101	Aortic valve stenosis: what do people know? A heart valve disease awareness survey of over 8,800 people aged 60 or over. EuroIntervention, 2016, 12, 883-889.	1.4	32
102	What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist?. Expert Opinion on Pharmacotherapy, 2011, 12, 1835-1844.	0.9	31
103	The evaluation of esophageal stenting complications in palliative treatment of dysphagia related to esophageal cancer. Medical Science Monitor, 2012, 18, CR323-CR329.	0.5	31
104	Effects of pentoxifylline on inflammatory markers and blood pressure. Journal of Hypertension, 2016, 34, 2318-2329.	0.3	31
105	Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis. Lipids in Health and Disease, 2019, 18, 188.	1.2	31
106	Acute Kidney Injury in COVID-19. International Journal of Molecular Sciences, 2021, 22, 8081.	1.8	31
107	Anti-oxidant activity of spermine and spermidine re-evaluated with oxidizing systems involving iron and copper ions. International Journal of Biochemistry and Cell Biology, 2006, 38, 69-81.	1.2	30
108	Heart function disturbances in chronic kidney disease $\hat{a} \in \text{``echocardiographic indices.}$ Archives of Medical Science, 2014, 6, 1109-1116.	0.4	30

#	Article	IF	CITATIONS
109	Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 4618.	1.8	30
110	The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis. Drugs, 2017, 77, 1187-1197.	4.9	29
111	Assessment of the Relationship between Lipid Parameters and Obesity Indices in Non-Diabetic Obese Patients: A Preliminary Report. Medical Science Monitor, 2014, 20, 2683-2688.	0.5	29
112	Current problems in hypertension and nephrology. Expert Opinion on Pharmacotherapy, 2010, 11, 2575-2578.	0.9	28
113	Oxidative Stress in ESRD Patients on Dialysis and the Risk of Cardiovascular Diseases. Antioxidants, 2020, 9, 1079.	2.2	28
114	Prevention of sudden cardiac death in patients with chronic kidney disease. BMC Nephrology, 2012, 13, 162.	0.8	27
115	Biomarkers and Echocardiographic Predictors of Myocardial Dysfunction in Patients with Hypertension. Scientific Reports, 2015, 5, 8916.	1.6	27
116	The Role of the Microbiome-Brain-Gut Axis in the Pathogenesis of Depressive Disorder. Nutrients, 2022, 14, 1921.	1.7	27
117	Effects of coenzyme Q10 supplementation on activities of selected antioxidative enzymes and lipid peroxidation in hypertensive patients treated with indapamide. A pilot study. Archives of Medical Science, 2010, 4, 513-518.	0.4	26
118	Blood Pressure Levels and Stroke: J-curve Phenomenon?. Current Hypertension Reports, 2013, 15, 575-581.	1.5	26
119	The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy $\hat{a} \in \text{``} 5$ -year follow-up. Lipids in Health and Disease, 2013, 12, 47.	1.2	25
120	State of the art paper Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease. Archives of Medical Science, 2013, 6, 1019-1027.	0.4	25
121	Sudden cardiac death in CKD patients. International Urology and Nephrology, 2015, 47, 971-982.	0.6	25
122	Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study. Lipids in Health and Disease, 2016, 15, 22.	1.2	25
123	Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. Scientific Reports, 2016, 6, 30060.	1.6	25
124	Association between phenotypic familial hypercholesterolaemia and telomere length in US adults: results from a multi-ethnic survey. European Heart Journal, 2018, 39, 3635-3640.	1.0	25
125	Increased hydrogen peroxide concentration in the exhaled breath condensate of stable COPD patients after nebulized N-acetylcysteine. Pulmonary Pharmacology and Therapeutics, 2007, 20, 281-289.	1.1	24
126	Elevated cholesterol reduces acetylsalicylic acid-mediated platelet acetylation. Biochimica Et Biophysica Acta - General Subjects, 2007, 1770, 1651-1659.	1.1	24

#	Article	IF	CITATIONS
127	Endothelial Dysfunction in Patients with Noncomplicated and Complicated Hypertension. Clinical and Experimental Hypertension, 2009, 31, 20-30.	0.5	24
128	Statins in patients with chronic kidney disease: why, who and when? Expert Opinion on Pharmacotherapy, 2010, 11, 2665-2674.	0.9	24
129	Sleep changes following statin therapy: a systematic review and meta-analysis of randomized placebo-controlled polysomnographic trials. Archives of Medical Science, 2015, 11, 915-26.	0.4	24
130	Current Place of Beta-Blockers in the Treatment of Hypertension. Current Vascular Pharmacology, 2010, 8, 733-741.	0.8	23
131	Impact of Vitamin D on the Cardiovascular System in Advanced Chronic Kidney Disease (CKD) and Dialysis Patients. Nutrients, 2018, 10, 709.	1.7	23
132	Is a High HDL-Cholesterol Level Always Beneficial?. Biomedicines, 2021, 9, 1083.	1.4	22
133	Ticagrelora new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?. Medical Science Monitor, 2009, 15, MS24-30.	0.5	22
134	What Is the Role of Gut Microbiota in Obesity Prevalence? A Few Words about Gut Microbiota and Its Association with Obesity and Related Diseases. Microorganisms, 2022, 10, 52.	1.6	22
135	Increased Levels of Soluble TNF-α Receptors and Cellular Adhesion Molecules in Patients Undergoing Bioincompatible Hemodialysis. American Journal of Nephrology, 2006, 26, 437-444.	1.4	21
136	Is Polymorphism within <i>eNOS</i> Gene Associated With the Late Onset of Myocardial Infarction? A Pilot Study. Angiology, 2009, 60, 588-595.	0.8	21
137	The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. Pharmacological Research, 2017, 122, 105-117.	3.1	21
138	The Use of Plant Sterols and Stanols as Lipid-Lowering Agents in Cardiovascular Disease. Current Pharmaceutical Design, 2017, 23, 2488-2495.	0.9	21
139	Increased hydrogen peroxide in the exhaled breath of uraemic patients unaffected by haemodialysis. Nephrology Dialysis Transplantation, 2004, 19, 158-163.	0.4	20
140	Reduced Blood Platelet Sensitivity to Aspirin in Coronary Artery Disease: Are Dyslipidaemia and Inflammatory States Possible Factors Predisposing to Subâ€optimal Platelet Response to Aspirin?. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 503-509.	1.2	20
141	Hypertension and kidney disease. Journal of Hypertension, 2012, 30, 457-462.	0.3	20
142	Prosarcopenic Effects of Statins May Limit Their Effectiveness in Patients with Heart Failure. Trends in Pharmacological Sciences, 2018, 39, 331-353.	4.0	20
143	Atrial fibrillation as a nonpsychiatric predictor of delirium after cardiac surgery: a pilot study. Medical Science Monitor, 2008, 14, CR286-291.	0.5	20
144	Effect of methoxy polyethylene glycol-epoetin beta on oxidative stress in predialysis patients with chronic kidney disease. Medical Science Monitor, 2013, 19, 954-959.	0.5	19

#	Article	IF	CITATIONS
145	A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients. Pharmacological Research, 2016, 111, 343-356.	3.1	19
146	Relationship between long noncoding RNAs and physiological risk factors of cardiovascular disease. Journal of Clinical Lipidology, 2017, 11, 617-623.	0.6	19
147	Genetic determinants of cardiovascular disease: the renin-angiotensin-aldosterone system, paraoxonases, endothelin-1, nitric oxide synthase and adrenergic receptors. In Vivo, 2009, 23, 797-812.	0.6	19
148	The effect of a platelet cholesterol modulation on the acetylsalicylic acid-mediated blood platelet inhibition in hypercholesterolemic patients. European Journal of Pharmacology, 2011, 658, 91-97.	1.7	18
149	Statins and dilated cardiomyopathy: do we have enough data?. Expert Opinion on Investigational Drugs, 2011, 20, 315-323.	1.9	18
150	Dronedarone: An overview. Annals of Medicine, 2012, 44, 60-72.	1.5	18
151	Renalase, Hypertension, and Kidney — The Discussion Continues. Angiology, 2013, 64, 181-187.	0.8	18
152	The influence of the pleiotropic action of erythropoietin and its derivatives on nephroprotection. Medical Science Monitor, 2013, 19, 599-605.	0.5	18
153	Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease. Expert Opinion on Investigational Drugs, 2015, 24, 603-610.	1.9	18
154	miRNA biomarkers in renal disease. International Urology and Nephrology, 2022, 54, 575-588.	0.6	18
155	Acute Coronary Syndromes in Patients with Chronic Kidney Disease. Current Vascular Pharmacology, 2013, 11, 758-767.	0.8	18
156	N-terminal brain natriuretic propeptide levels correlate with procalcitonin and C-reactive protein levels in septic patients. Cellular and Molecular Biology Letters, 2007, 12, 162-75.	2.7	17
157	Biochemical Markers in the Prediction of Contrast-induced Acute Kidney Injury. Current Medicinal Chemistry, 2021, 28, 1234-1250.	1.2	17
158	Statins in the prevention of postoperative atrial fibrillation: Is there really no effect?. American Heart Journal, 2008, 155, e53.	1.2	16
159	Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?. Expert Opinion on Pharmacotherapy, 2018, 19, 1857-1865.	0.9	16
160	Oxidative Stress-Related Susceptibility to Aneurysm in Marfan's Syndrome. Biomedicines, 2021, 9, 1171.	1.4	16
161	Vernakalant hydrochloride for the treatment of atrial fibrillation. Expert Opinion on Investigational Drugs, 2009, 18, 1929-1937.	1.9	15
162	Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients. International Urology and Nephrology, 2018, 50, 339-345.	0.6	15

#	Article	IF	Citations
163	Characteristics of Clear Cell Papillary Renal Cell Carcinoma (ccpRCC). International Journal of Molecular Sciences, 2022, 23, 151.	1.8	15
164	Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge. International Urology and Nephrology, 2015, 47, 805-813.	0.6	14
165	Cholesterol Disturbances and the Role of Proper Nutrition in CKD Patients. Nutrients, 2019, 11, 2820.	1.7	14
166	Metabolomic Profile in Venous Thromboembolism (VTE). Metabolites, 2021, 11, 495.	1.3	14
167	Pathomechanisms of Immunological Disturbances in $\hat{I}^2$ -Thalassemia. International Journal of Molecular Sciences, 2021, 22, 9677.	1.8	14
168	Evaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney Disease. Current Vascular Pharmacology, 2016, 14, 360-367.	0.8	14
169	Ageing, Age-Related Cardiovascular Risk and the Beneficial Role of Natural Components Intake. International Journal of Molecular Sciences, 2022, 23, 183.	1.8	14
170	Risk Factors for Atrial Fibrillation in Adult Patients in Long-Term Observation Following Surgical Closure of Atrial Septal Defect Type II. Thoracic and Cardiovascular Surgeon, 2006, 54, 259-263.	0.4	13
171	Natriuretic Peptides in Septic Patients. Current Medicinal Chemistry, 2009, 16, 4020-4031.	1.2	13
172	Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease. Expert Opinion on Pharmacotherapy, 2016, 17, 2049-2056.	0.9	13
173	Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial. BMC Nephrology, 2017, 18, 24.	0.8	13
174	Diabetes and Cardiovascular Risk in Renal Transplant Patients. International Journal of Molecular Sciences, 2021, 22, 3422.	1.8	13
175	The Correlation between Lipid Metabolism Disorders and Prostate Cancer. Current Medicinal Chemistry, 2021, 28, 2048-2061.	1.2	13
176	Erythropoietin update 2011. Medical Science Monitor, 2011, 17, RA240-RA247.	0.5	13
177	Cytisine - From the Past to the Future. Current Pharmaceutical Design, 2019, 24, 4413-4423.	0.9	13
178	Renal Cell Cancer and Obesity. International Journal of Molecular Sciences, 2022, 23, 3404.	1.8	13
179	Increased whole blood chemiluminescence in patients with chronic renal failure independent of hemodialysis treatment. Archivum Immunologiae Et Therapiae Experimentalis, 2006, 54, 347-355.	1.0	12
180	Evaluation of selected parameters of the antioxidative system in patients with type 2 diabetes in different periods of metabolic compensation. Archivum Immunologiae Et Therapiae Experimentalis, 2007, 55, 335-340.	1.0	12

#	Article	IF	CITATIONS
181	Aortic stiffness in diabetes mellitus – association with glutamine and heat shock protein 70 expression: a pilot study based on an experimental rodent model. Expert Opinion on Therapeutic Targets, 2009, 13, 267-274.	1.5	12
182	The profile of selected single nucleotide polymorphisms in patients with hypertension and heart failure with preserved and mid-range ejection fraction. Scientific Reports, 2017, 7, 8974.	1.6	12
183	The Role of Metabolic Factors in Renal Cancers. International Journal of Molecular Sciences, 2020, 21, 7246.	1.8	12
184	Serum Antioxidant Capacity is Preserved in Peritoneal Dialysis Contrary to Its Robust Depletion After Hemodialysis and Hemodiafiltration Sessions. Therapeutic Apheresis and Dialysis, 2010, 14, 209-217.	0.4	11
185	Molecular Interactions of Arterial Hypertension in Its Target Organs. International Journal of Molecular Sciences, 2021, 22, 9669.	1.8	11
186	Mineralocorticoid Receptor Antagonistsâ€"Use in Chronic Kidney Disease. International Journal of Molecular Sciences, 2021, 22, 9995.	1.8	11
187	The Problem of Atrial Fibrillation in Patients with Chronic Kidney Disease. Current Vascular Pharmacology, 2016, 14, 260-265.	0.8	11
188	Increased Exhaled H2O2 and Impaired Lung Function in Patients Undergoing Bioincompatible Hemodialysis. International Journal of Artificial Organs, 2007, 30, 879-888.	0.7	10
189	The Role of Trimetazidine After Acute Myocardial Infarction. Current Vascular Pharmacology, 2008, 6, 282-291.	0.8	10
190	Effects of resorcylidene aminoguanidine (RAG) on selected parameters of isolated rat liver mitochondria. Chemico-Biological Interactions, 2009, 179, 280-287.	1.7	10
191	Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study. Lipids in Health and Disease, 2010, 9, 21.	1.2	10
192	Gender Differences in the Treatment of Ischemic Heart Disease. Current Pharmaceutical Design, 2011, 17, 1059-1069.	0.9	10
193	The Knowledge and Awareness of Hypertension Among Patients With Hypertension in Central Poland. Angiology, 2014, 65, 525-532.	0.8	10
194	A systematic review and meta-analysis of clinical trials investigating the effects of flaxseed supplementation on plasma C-reactive protein concentrations. Archives of Medical Science, 2019, 15, 12-22.	0.4	10
195	Cholesterol Subfraction Analysis in Patients with Acute Coronary Syndrome. Current Vascular Pharmacology, 2019, 17, 365-375.	0.8	10
196	Emerging Anti-Atherosclerotic Therapies. International Journal of Molecular Sciences, 2021, 22, 12109.	1.8	10
197	Pharmacogenetics of Drugs Used in the Treatment of Cancers. Genes, 2022, 13, 311.	1.0	10
198	Clinical Implications of Non-Invasive Measurement of Central Aortic Blood Pressure. Current Vascular Pharmacology, 2010, 8, 747-752.	0.8	9

#	Article	IF	Citations
199	Hypertension - Current Natural Strategies to Lower Blood Pressure. Current Pharmaceutical Design, 2017, 23, 2453-2461.	0.9	9
200	Lipids, Blood Pressure, Kidney-what was New in 2012?. International Journal of Pharmacology, 2012, 8, 659-678.	0.1	9
201	Biological Role of Vitamin K—With Particular Emphasis on Cardiovascular and Renal Aspects. Nutrients, 2022, 14, 262.	1.7	9
202	TNF- $\hat{l}\pm$ priming effect on polymorphonuclear leukocyte reactive oxygen species generation and adhesion molecule expression in hemodialyzed patients. Archivum Immunologiae Et Therapiae Experimentalis, 2006, 54, 209-215.	1.0	8
203	Effect of Oral Fructose Load on Serum Uric Acid and Lipids in Kidney Transplant Recipients Treated With Cyclosporine or Tacrolimus. Transplantation Proceedings, 2009, 41, 188-191.	0.3	8
204	Morphine-mediated alteration of hypertension-related gene expression in human white blood cells and multilineage progenitor cells. Journal of Human Hypertension, 2010, 24, 713-720.	1.0	8
205	Prognostic value of plasma N-terminal pro-B-type natriuretic peptide concentration in patients with normal and impaired left ventricular systolic function undergoing surgery for abdominal aortic aneurysm. Archives of Medical Science, 2011, 4, 642-647.	0.4	8
206	What is the risk of hyperkalaemia in heart failure?. Expert Opinion on Pharmacotherapy, 2011, 12, 2329-2338.	0.9	8
207	Renalase is Removed by Kidneys and During Dialysis – Excess Related to CKD Complications?. Current Vascular Pharmacology, 2015, 13, 134-140.	0.8	8
208	Assessment of the relationship between selected cardiovascular risk factors and the indices of intima-media thickness and coronary artery calcium score in various stages of chronic kidney disease. International Urology and Nephrology, 2015, 47, 2003-2012.	0.6	8
209	Novel drugs for heart rate control in heart failure. Heart Failure Reviews, 2018, 23, 517-525.	1.7	8
210	Levosimendan - a calcium sensitising agent with potential anti-arrhythmic properties. International Journal of Clinical Practice, 2010, 64, 1148-1154.	0.8	7
211	Examination of serum pregnancy-associated plasma protein A clinical value in acute coronary syndrome prediction and monitoring. Archives of Medical Science, 2013, 1, 14-20.	0.4	7
212	The occurrence of atrial fibrillation in dialysis patients and its association with left atrium volume before and after dialysis. International Urology and Nephrology, 2017, 49, 1071-1077.	0.6	7
213	High-Sensitivity C-Reactive Protein Relationship with Metabolic Disorders and Cardiovascular Diseases Risk Factors. Life, 2021, 11, 742.	1.1	7
214	Anticoagulant Prevention in Patients with Atrial Fibrillation: Alternatives to Vitamin K Antagonists. Current Pharmaceutical Design, 2013, 19, 3816-3826.	0.9	7
215	L-arginine improves hemodynamic function and coronary flow in an experimental model of ischemia-reperfusion injury. Annals of Transplantation, 2006, $11$ , 28-34.	0.5	7
216	Assessment of blood flow in posterior ciliary arteries and its correlation with intraocular and arterial blood pressures in patients with open angle glaucoma. Medical Science Monitor, 2010, 16, CR501-9.	0.5	7

#	Article	IF	Citations
217	Left atrial and left atrial appendage systolic function in patients with post-myocardial distal blocks. Archives of Medical Science, 2010, 6, 892-899.	0.4	6
218	Correlation of the severity of diabetic retinopathy and the heart muscle perfusion in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2011, 25, 253-257.	1.2	6
219	The Influence of Dietary Interventions on Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Nutrients, 2021, 13, 2065.	1.7	6
220	Established and potential echocardiographic markers of embolism and their therapeutic implications in patients with ischemic stroke. Cardiology Journal, 2019, 26, 438-450.	0.5	6
221	Empagliflozin—A New Chance for Patients with Chronic Heart Failure. Pharmaceuticals, 2022, 15, 47.	1.7	6
222	Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?. Pharmaceuticals, 2022, 15, 739.	1.7	6
223	Obesity and postoperative atrial fibrillation. Is there no connection?. American Heart Journal, 2008, 156, e5.	1.2	5
224	Pattern replication in blends of semiconducting and insulating polymers casted by horizontal dipping. Journal of Polymer Science, Part B: Polymer Physics, 2013, 51, 1419-1426.	2.4	5
225	Selected cardiovascular risk factors in early stages of chronic kidney disease. International Urology and Nephrology, 2020, 52, 303-314.	0.6	5
226	Are Nutraceuticals Beneficial in Chronic Kidney Disease?. Pharmaceutics, 2021, 13, 231.	2.0	5
227	Letter by Banach et al Regarding Article, "Postoperative Treatment With Carvedilol, a $\hat{I}^2$ -Adrenergic Blocker, Prevents Paroxysmal Atrial Fibrillation After Coronary Artery Bypass Grafting". Circulation Journal, 2008, 72, 1388.	0.7	4
228	Investigating dysfunctional-hdl in selected groups of patients at high risk of cardiovascular events (dys-hdl study) - Protocol and organization. Atherosclerosis, 2014, 235, e171-e172.	0.4	4
229	Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-9.	1.9	4
230	Effects of tibolone on fibrinogen and antithrombin III: A systematic review and meta-analysis of controlled trials. Pharmacological Research, 2017, 124, 64-73.	3.1	4
231	Are Markers of Cardiac Dysfunction Useful in the Assessment of Cardiovascular Risk in Dialysis Patients?. Current Pharmaceutical Design, 2017, 23, 3024-3033.	0.9	4
232	Diabetes-induced Alterations in HDL Subfractions Distribution. Current Pharmaceutical Design, 2020, 26, 3341-3348.	0.9	4
233	Lipoprotein Subfractions, Uric Acid and Cardiovascular Risk in End-Stage Renal Disease (ESRD) Patients. Current Vascular Pharmacology, 2017, 15, 123-134.	0.8	4
234	The behaviour of bone mineral density and bone metabolism index in young and menopausal women with the consideration of body mass index. Medical Science Monitor, 2010, 16, CR342-7.	0.5	4

#	Article	IF	CITATIONS
235	Qualification for endoscopic retrograde cholangiopancreatography in the diagnosis and treatment of extrahepatic cholestasis caused by choledocholithiasis. Archives of Medical Science, 2015, 6, 1213-1216.	0.4	3
236	Impact of anemia treatment with methoxy polyethylene glycol-epoetin beta on polymorphonuclear cells apoptosis in predialysis patients with chronic kidney disease. Pharmacological Reports, 2015, 67, 842-845.	1.5	3
237	Ocena metabolizmu kostnego, oznaczenie wskaźnika metabolizmu kostnego i okreŷlenie zakresu jego wartoÅ·ci prawidÅ,owych u mÅ,odych, zdrowych kobiet Medical Science Monitor, 2011, 17, CR563-CR571.	0.5	3
238	The influence of uremic high cystatin C concentration on neutrophil apoptosis and selected neutrophil functions isolated from healthy subjects. Medical Science Monitor, 2012, 18, CR667-CR673.	0.5	3
239	Patients with Prehypertension – Do we have Enough Evidence to Treat them?. Current Vascular Pharmacology, 2014, 12, 586-597.	0.8	3
240	High sensitivity C-reactive protein, NT-proBNP and hemodynamic left ventricular function in acute coronary syndrome without ST segment elevation - a preliminary report. Medical Science Monitor, 2010, 16, CR313-7.	0.5	3
241	Effectiveness comparison of endoscopic methods of non-varicose upper gastrointestinal bleeding treatment. Archives of Medical Science, 2010, 4, 599-604.	0.4	2
242	Progression of diabetic retinopathy correlated with muscle perfusion disturbances of the lower limbs, with clinically important diagnostic recommendations. Archives of Medical Science, 2010, 6, 904-911.	0.4	2
243	High prevalence of vitamin D deficiency and its association with metabolic disorders in elderly patients. Family Medicine and Primary Care Review, 2017, 19, 372-376.	0.1	2
244	Biomarkers of Cardiovascular Risk in Haemodialysis Patients. Current Pharmaceutical Design, 2018, 23, 6086-6095.	0.9	2
245	Influence of pharmacological treatment on blood flow and muscle perfusion in patients with obliterative atheromatosis assessed with isotopic methods. A pilot study. Medical Science Monitor, 2010, 16, CR622-7.	0.5	2
246	Coronary artery atherosclerosis in patients with the initial and the early stage of chronic renal failure. Open Medicine (Poland), 2009, 4, 32-36.	0.6	1
247	Are Polymorphisms within Endothelial Nitric Oxide Synthase Good Predictors of Coronary Artery Disease. Cardiology, 2010, 116, 268-270.	0.6	1
248	P2.5 SEX-DEPENDENT DIFFERENCES IN OBESITY INDICES AND INFLAMMATORY MARKERS IN NON-DIABETIC OBESE PATIENTS. Artery Research, 2015, 12, 7.	0.3	1
249	Definition and Characteristics of Hypertension Associated with Chronic Kidney Disease: Epidemiological Data., 2017,, 13-23.		1
250	Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases. International Journal of Molecular Sciences, 2017, 18, 1248.	1.8	1
251	Radioisotopic assessment of bone metabolism of the operated vertebra after inter-process stabilizer implantation in the lumbar segment of the spine. Archives of Medical Science, 2017, 1, 174-182.	0.4	1
252	Statins and Fibrates: Should They Be Recommended?., 2015, , 11-23.		1

#	Article	IF	Citations
253	Wytyczne PTL/KLRwP/PTK dotyczące postępowania w zaburzeniach lipidowych dla lekarzy rodzinnych 2016. Kardiologia Polska, 2017, 74, 127-168.	0.3	1
254	Left atrial function in patients with renal transplantation. Medical Science Monitor, 2002, 8, CR508-11.	0.5	1
255	N-TERMINAL BRAIN NATRIURETIC PROPEPTIDE LEVELS CORRELATE WITH PROCALCITONIN AND C-REACTIVE PROTEIN LEVELS IN SEPTIC PATIENTS. Shock, 2006, 26, 36.	1.0	0
256	Integrin CD11a/CD18, CD11b/CD18 and CD69 expression in patients after renal transplantation. Open Medicine (Poland), 2007, 2, 154-158.	0.6	0
257	IL-2, IL-6 and IL-8 levels remain unaltered in the course of immunosuppressive therapy after renal transplantation. Open Medicine (Poland), 2008, 3, 199-202.	0.6	0
258	Mortality in surgical units and postoperative care. Open Medicine (Poland), 2008, 3, 346-357.	0.6	0
259	Microarray technology in the study of genetic determinants of cardiovascular diseases. Open Medicine (Poland), 2009, 4, 1-10.	0.6	0
260	PCV5 The Effeects of Statins on Blood Presure in Normotensive or Hypertensive Subjects-a Meta-Analysis of 18 Randomized Controlled Trials Involving 5628 Participants. Value in Health, 2012, 15, A629-A630.	0.1	0
261	Obesity indices and inflammatory markers in obese non-diabetic normo- And hypertensive patients. a comparative pilot study. Atherosclerosis, 2014, 235, e136-e137.	0.4	0
262	Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. Atherosclerosis, 2015, 241, e8.	0.4	0
263	Markers of increased cardiovascular risk in elderly patients with chronic kidney disease: A preliminary study. Atherosclerosis, 2015, 241, e184.	0.4	0
264	Lack of efficacy of resveratrol on cardiovascular parameters? Results from a systematic review and meta-analysis of randomized controlled trials. Atherosclerosis, 2015, 241, e190.	0.4	0
265	A systematic review and meta-analysis on the effect of statins on plasma asymmetric dimethylarginine concentrations. Atherosclerosis, 2015, 241, e199.	0.4	0
266	The assessment of selected markers of cardiac dysfunction in the analysis of cardiovascular risk in dialysis patients. Atherosclerosis, 2017, 263, e273.	0.4	0
267	Prevalence of insomnia and use of hypnotics in seniors from the Åodz Province, Poland. Family Medicine and Primary Care Review, 2019, 21, 17-22.	0.1	0
268	92 Low BMI as an independent risk factor of death in patients with severe heart failure subjected to aortic valve replacement. European Journal of Heart Failure, Supplement, 2007, 6, 21-21.	0.2	0
269	2021 PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on the diagnosis and therapy of lipid disorders in Poland. Diagnostyka Laboratoryjna I WiadomoÅci PTDL, 2021, 57, 1-99.	0.0	0
270	Evaluation of the effectiveness of methods of endoscopic treatment of bleeding from the duodenal mucosa. Polski Merkuriusz Lekarski, 2015, 38, 77-81.	0.3	0